Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings